|
| Press Releases |
|
 |
|
| Saturday, June 1, 2024 |
|
|
Avance Clinical通过与Julius Clinical合作，在欧洲扩展专门的中枢神经系统、心血管代谢和罕见疾病的CRO服务 |
| 澳大利亚和北美市场领先的获奖CRO公司Avance Clinical与Julius Clinical签署了一份谅解备忘录（MOU）。Julius Clinical是一家在中枢神经系统、心血管代谢和罕见疾病领域的专业CRO，在该地区拥有广泛的站点关系。 more info >> |
|
| Friday, May 31, 2024 |
|
|
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical |
| Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS, cardiometabolic, and rare diseases specialist CRO with extensive site relationships in the region. more info >> |
|
| Thursday, May 9, 2024 |
|
|
Avance Clinical, 한국에서 새로운 임상 운영으로 APAC 지역으로 더 확장 |
| Avance Clinical, 은 수상 경력이 있는 호주 및 북미 지역의 생명공학 분야 선도 CRO로서, 2024년 5월 8일부터 10일까지 BIO Korea에 참가하고 한국 서울에서 새로운 임상 운영을 공식적으로 시작할 예정입니다. more info >> |
|
|
Avance Clinical 在亞太地區進一步擴張，韓國新的臨床運營 |
| more info >> |
|
|
Avance Clinical 在亚太地区进一步扩张，韩国新的临床运营 |
| Avance Clinical，这家屡获殊荣的澳大利亚和北美市场领先的生物技术公司CRO，将参加2024年5月8日至10日的韩国生物技术展，并将在韩国首尔正式开展新的临床运营。 more info >> |
|
| Wednesday, May 8, 2024 |
|
|
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea |
| Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, will attend BIO Korea (May 8-10, 2024) and formally open new clinical operations in Seoul, South Korea. more info >> |
|
| Monday, April 22, 2024 |
|
|
Avance Clinical은 4월 23일부터 25일까지 보스턴에서 열리는 세계 고아약 학회에서 임상 우수성을 선보입니다 |
| 바이오테크 기업을 위한 수상 경력을 가진 북미와 호주 시장을 선도하는 CRO인 Avance Clinical은 보스턴에서 열리는 세계 고아약 학회 참석하여 (2024년 4월 23일부터 25일까지) 바이오테크 기업들에게 자신들의 희귀 질환 의약품 개발 전문지식을 공유할 것입니다 (부스 #730). more info >> |
|
| Saturday, April 20, 2024 |
|
|
Avance Clinical 在4月23日至25日波士頓世界孤兒藥物會議上展示臨床突出成績 |
| Avance Clinical，作為备受讚譽的北美和澳大利亞領先生物技術公司的CRO，將出席2024年波士頓 世界孤兒藥物會議（4月23日至25日），與生物技術公司分享他們在罕見疾病藥物開發方面的專業知識（展台號：730）。 more info >> |
|
|
Avance Clinical 在4月23日至25日波士顿世界孤儿药物会议上展示临床突出成绩 |
| Avance Clinical，作为备受赞誉的北美和澳大利亚领先生物技术公司的CRO，将出席2024年波士顿 世界孤儿药物会议（4月23日至25日），与生物技术公司分享他们在罕见疾病药物开发方面的专业知识（展台号：730）。 more info >> |
|
| Friday, April 19, 2024 |
|
|
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25 |
| Avance Clinical, the award-winning North American and Australian market-leading CRO for biotechs, will attend World Orphan Drug Conference in Boston (April 23-25, 2024) to share their rare diseases drug development expertise with biotechs (booth #730). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 17:34: JST
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元
Feb 6, 2026 16:56 HKT/SGT
|
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元
Feb 6, 2026 16:50 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
トヨタ、役員人事を発表
Feb 6, 2026 16:00: JST
|
|
|
Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors
Feb 6, 2026 15:55 HKT/SGT
|
|
|
Muyuan Foods Makes Hong Kong Debut Today: Strong Cornerstone Investor Backing Fuels Rapid Earnings Growth, Embarking on New Journey of Internationalization
Feb 6, 2026 15:40 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 15:17: JST
|
|
|
牧原股份港股上市：全球生豬养殖龍頭 價值成長兼具
Feb 6, 2026 15:08 HKT/SGT
|
|
|
牧原股份港股上市：全球生猪养殖龙头 价值成长兼具
Feb 6, 2026 15:01 HKT/SGT
|
|
|
優異供應鏈賦能與國際化佈局雙輪驅動 綠茶開啟高質量成長新篇章
Feb 6, 2026 14:47 HKT/SGT
|
|
|
优异供应链赋能与国际化布局双轮驱动 绿茶开启高质量成长新篇章
Feb 6, 2026 14:33 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
